Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals plc is a biopharmaceutical company operating in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients aged seven years and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Incorporated in 2015, it is headquartered in Dublin 2, Ireland, and as of February 12, 2026, operates as a subsidiary of Alkermes plc.